National guidelines usually only propose PSMA-PET in case of recurrent disease as an optional method (German S3 guideline) or don’t even mention PSMA-PET (NCCN prostate cancer guidelines version 2.2017) [23, 24]. This evidence concerns the gene FOLH1 and prostate carcinoma.